Literature DB >> 3102606

Effects of interferon-gamma on proto-oncogene expression during induction of human monocytic differentiation.

E Sariban, T Mitchell, J Griffin, D W Kufe.   

Abstract

Activation of the proto-oncogenes c-fos, c-fms, and c-sis has been associated with monocytic differentiation. In the present study, we monitored the relationship of c-myc, c-fos, c-fms, and c-sis expression to interferon-gamma (IFN-gamma)-induced monocytic differentiation of human HL-60 promyelocytic leukemia cells. Treatment of HL-60 cells with 500 U/ml IFN-gamma arrested cell proliferation after 3 days. Appearance of the monocytic phenotype was manifested within 24 hr of IFN-gamma exposure by: increased nitroblue tetrazolium reduction; increased cell surface expression of the HLA-DR, Mo1, and MY4 antigens; and induction of transcripts for the second component of complement (C2) and tumor necrosis factor. In contrast, c-myc expression decreased as a later event after 72 hr of IFN-gamma exposure, and c-fos transcripts remained undetectable until 5 days of treatment. Furthermore, c-fms RNA and transcripts for the macrophage marker apolipoprotein E were induced only after 7 days. Finally, expression of the c-sis proto-oncogene at the RNA and protein levels remained undetectable after induction with IFN-gamma. These findings would thus suggest that declines in c-myc RNA, as well as induction of c-fos, c-fms, and c-sis expression, are not requisite events in the commitment of HL-60 cells to IFN-gamma-induced monocytic differentiation. Expression of c-fos and c-fms, however, is associated with acquisition of markers associated with maturation to macrophages.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102606

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Interferon gamma abrogates the differentiation block in v-myc-expressing U-937 monoblasts.

Authors:  F Oberg; L G Larsson; R Anton; K Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

2.  Overexpression of prothymosin alpha accelerates proliferation and retards differentiation in HL-60 cells.

Authors:  P Rodríguez; J E Viñuela; L Alvarez-Fernández; M Buceta; A Vidal; F Domínguez; J Gómez-Márquez
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

3.  Multinucleated giant cells generated in vitro. Terminally differentiated macrophages with down-regulated c-fms expression.

Authors:  H Kreipe; H J Radzun; P Rudolph; J Barth; M L Hansmann; K Heidorn; M R Parwaresch
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

4.  Interferon gamma encapsulated into liposomes enhances the activity of monocytes and natural killer cells and has antiproliferative effects on tumor cells in vitro.

Authors:  I Rutenfranz; A Bauer; H Kirchner
Journal:  Blut       Date:  1990-07

5.  Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA.

Authors:  J H Pierce; E Di Marco; G W Cox; D Lombardi; M Ruggiero; L Varesio; L M Wang; G G Choudhury; A Y Sakaguchi; P P Di Fiore
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  c-fos mRNA expression in macrophages is downregulated by interferon-gamma at the posttranscriptional level.

Authors:  D Radzioch; L Varesio
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

7.  Posttranscriptional stabilization of c-fms mRNA by a labile protein during human monocytic differentiation.

Authors:  B Weber; J Horiguchi; R Luebbers; M Sherman; D Kufe
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

8.  Effect of human interferons on morphological differentiation and suppression of N-myc gene expression in human neuroblastoma cells.

Authors:  H Watanabe; T Chisaka; T Higuchi; A Tanaka; Y Horii; T Sugimoto; J Imanishi
Journal:  Jpn J Cancer Res       Date:  1989-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.